SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

CAC 40 NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

COMPANY SEARCH RESULT

Sanofi-Aventis: Click to view the issuer\'s details

Last update : 13/03/2018  >View issuer details

2019.03.13 | 19:29 | Permanent Information Releases / Operations

English version HTML (w) Mail

puce Sanofi successfully prices EUR 2 billion of bond issues - HTML (w)

2019.03.13 | 19:29 | Permanent Information Releases / Operations

French version HTML (w) Mail

puce Sanofi place des emprunts obligataires de 2 milliards d'euros - HTML (w)

2019.03.08 | 20:49 | Permanent Information Releases / Notification of availability

English version HTML (w) Mail

puce Sanofi: Filing of the 2018 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report - HTML (w)

2019.03.08 | 20:49 | Permanent Information Releases / Notification of availability

French version HTML (w) Mail

puce Sanofi : Dépôt du Document de Référence 2018, contenant le Rapport Financier Annuel, et du « Form 20-F » américain - HTML (w)

2019.03.08 | Periodic information / Registration document

French version PDF Mail

puce Sanofi-Aventis : Document de Référence 2018 - PDF (5Mb)

2019.03.01 | 14:13 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Sanofi: CHMP recommends approval of Dupixent® (dupilumab) for asthma indication - HTML (w)

2019.03.01 | 14:13 | Permanent Information Releases / General Company News

French version HTML (w) Mail

puce Sanofi : Le CHMP recommande l'approbation de l'indication de Dupixent® (dupilumab) dans l'asthme - HTML (w)

2019.03.01 | 14:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Sanofi : CHMP recommends ZynquistaTM (sotagliflozin) for the treatment of adults with type 1 diabetes - HTML (w)

2019.03.01 | 14:00 | Permanent Information Releases / General Company News

French version HTML (w) Mail

puce Sanofi : Le CHMP recommande ZynquistaTM (sotagliflozine) pour le traitement du diabète de type 1 chez l'adulte - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 2645